KalVista Pharmaceuticals (KALV) Profit After Tax Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 65.80% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 17.05% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -48.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -48.59% |
| Apr 30, 2025 | -16.97% |
| Oct 31, 2024 | -52.87% |
| Jul 31, 2024 | -59.75% |
| Apr 30, 2024 | -69.74% |
| Jan 31, 2024 | -36.26% |
| Oct 31, 2023 | -24.23% |
| Jul 31, 2023 | -9.87% |
| Apr 30, 2023 | -9.09% |
| Jan 31, 2023 | 5.18% |
| Oct 31, 2022 | -13.27% |
| Jul 31, 2022 | -43.04% |
| Apr 30, 2022 | -61.23% |
| Jan 31, 2022 | -123.60% |
| Oct 31, 2021 | -88.47% |
| Jul 31, 2021 | -48.96% |
| Apr 30, 2021 | -127.12% |
| Jan 31, 2021 | -8.15% |
| Oct 31, 2020 | -76.62% |
| Jul 31, 2020 | -47.37% |
| Apr 30, 2020 | 22.77% |
| Jan 31, 2020 | -134.86% |
| Oct 31, 2019 | -78.66% |
| Jul 31, 2019 | -45.88% |
| Apr 30, 2019 | -1,197.72% |
| Jan 31, 2019 | 24.42% |
| Oct 31, 2018 | 33.73% |
| Jul 31, 2018 | -2.07% |
| Apr 30, 2018 | 84.36% |
| Jan 31, 2018 | 31.53% |
| Oct 31, 2017 | -51.23% |
| Jul 31, 2017 | -43.42% |
| Mar 31, 2016 | -27.45% |
| Dec 31, 2015 | -20.05% |
| Sep 30, 2015 | -24.93% |
| Jun 30, 2015 | -242.01% |
| Mar 31, 2015 | -157.27% |